COVID-19 readmissions during the first three epidemic periods in Orihuela, Spain: incidence, risk factors and letality

e202403023

Authors

  • Nuria Roig-Sánchez Servicio de Medicina Interna; Hospital Vega Baja. San Bartolomé (Alicante). España. / Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO). Valencia. España. https://orcid.org/0000-0003-3250-8071
  • Alberto Talaya Peñalver Servicio de Medicina Interna; Hospital Vega Baja. San Bartolomé (Alicante). España. / Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO). Valencia. España.
  • Noemí Poveda Ruiz Unidad de Enfermedades Infecciosas; Hospital Reina Sofía. Murcia. España.
  • Alfonso del Pozo Servicio de Medicina Interna; Hospital Vega Baja. San Bartolomé (Alicante). España. / Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO). Valencia. España.
  • Ana María Hernández Campillo Servicio de Hematología; Hospital Virgen de la Arrixaca. El Palmar (Murcia). España.
  • Alicia Pérez Bernabéu Servicio de Medicina Interna; Hospital Vega Baja. San Bartolomé (Alicante). España. / Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO). Valencia. España.
  • Belén Martínez-López Servicio de Medicina Interna; Hospital Vega Baja. San Bartolomé (Alicante). España. / Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO). Valencia. España.
  • Inmaculada González-Cuello Servicio de Medicina Interna; Hospital Vega Baja. San Bartolomé (Alicante). España. / Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO). Valencia. España.
  • María García-López Servicio de Medicina Interna; Hospital Vega Baja. San Bartolomé (Alicante). España. / Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO). Valencia. España.
  • Emilio Borrajo Brunete Servicio de Microbiología; Hospital Vega Baja. San Bartolomé (Alicante). España.
  • Philip Wikman-Jorgensen Servicio de Medicina Interna; Hospital Universitario San Juan de Alicante. Sant Joan d’Alacant (Alicante). España.
  • Jara Llenas-García Servicio de Medicina Interna; Hospital Vega Baja. San Bartolomé (Alicante). España. / Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO). Valencia. España. / Departamento de Medicina Clínica; Universidad Miguel Hernández. Elche. España.

Keywords:

SARS-CoV-2, COVID-19, Pneumonia, Readmission, Pandemic

Abstract

BACKGROUND // Readmission for COVID-19 is associated with high mortality, saturation of health services, and high costs. This study aimed to assess the incidence and risk factors of readmissions in COVID-19 patients in a regional hospital of Spain from February 2020 to March 2021.
METHODS // A retrospective cohort study describing the characteristics of adult patients readmitted within thirty days of discharge after being infected with SARS-CoV-2 was carried out. Readmission associated risk factors were analysed using a binary logistic regression model.
RESULTS // Of the 967 patients who survived their first COVID-19 admission, 70 (7.2%) were readmitted within thirty days. Of these, 34.3% presented pneumonia progression, 15.7% functional deterioration, and 12.9% other infections. The mortality rate during readmission was 28.6%. There were no statistically significant differences in the cumulative incidence of readmissions between the epidemic periods (p=0.241). Factors independently associated with readmission were: diabetes mellitus (aOR 1.96, 95%CI 1.07-3.57, p=0.030); acute kidney failure (aOR 2.69, 95%CI 1.43-5.07, p=0.002); not being a candidate for intensive care (aOR 7.68, 95% CI 4.28-13.80, p<0.001); and not being prescribed corticosteroids at discharge (aOR 2.15, 95% CI 1.04-4.44; p=0.039).
CONCLUSIONS // A substantial proportion of patients admitted due to COVID-19 are readmitted, and they carry a high letality. Diabetes mellitus, acute kidney failure, not being a candidate for ICU admission, and not being prescribed corticosteroids on discharge are independently associated with an increased risk of readmission.

Downloads

Download data is not yet available.

References

Carvalho T, Krammer F, Iwasaki A. The first 12 months of COVID-19: a timeline of immunological insights. Nat Rev Immunol. 2021;21:245-256.

Khan M, Adil SF, Alkhathlan HZ, Tahir MN, Saif S, Khan M et al. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far. Molecules. 2020;26:39.

WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. [Consultado el 18-04-2023]. Disponible en: https://covid19.who.int/

Loo WK, Hasikin K, Suhaimi A, Yee PL, Teo K, Xia K et al. Systematic Review on COVID-19 Readmission and Risk Factors: Future of Machine Learning in COVID-19 Readmission Studies. Front Public Health. 2022;10.

Vincent J-L, Levi M, Hunt BJ. Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. Lancet Respir Med. 2022;10:214-220.

Taboada M, González M, Alvarez A, Eiras M, Costa J, Álvarez J et al. First, second and third wave of COVID-19. What have we changed in the ICU management of these patients? Journal of Infection. 2021;82:e14-15.

Tyrrell CSB, Mytton OT, Gentry SV, Thomas-Meyer M, Allen JLY, Narula AA et al. Managing intensive care admissions when there are not enough beds during the COVID-19 pandemic: a systematic review. Thorax. 2021;76:302-312.

Soriano V, de Mendoza C, Gómez-Gallego F, Corral O, Barreiro P. Third wave of COVID-19 in Madrid, Spain. International Journal of Infectious Diseases. 2021;107:212-214.

Ramos-Martínez A, Parra-Ramírez LM, Morrás I, Carnevali M, Jiménez-Ibañez L, Rubio-Rivas M et al. Frequency, risk factors, and outcomes of hospital readmissions of COVID-19 patients. Sci Rep. 2021;11:13733.

Wiley Z, Kulshreshtha A, Li D, Kubes J, Kandiah S, Leung S et al. Clinical characteristics and social determinants of health associated with 30-day hospital readmissions of patients with COVID-19. Journal of Investigative Medicine. 2022;70:1406-1415.

Gwin M, Saleki M, Lampert H, Meo N, Bann M. Emergency department visits and readmissions after COVID-19 hospitalization: a cross-sectional analysis. Intern Emerg Med. 2021;16:1715-1718.

Kirkegaard C, Falcó-Roget A, Sánchez-Montalvá A, Valls Á, Clofent D, Campos-Varela I et al. Incidence and risk factors for early readmission after hospitalization for SARS-CoV-2 infection: results from a retrospective cohort study. Infection. 2022;50:371-380.

Akbari A, Fathabadi A, Razmi M, Zarifian A, Amiri M, Ghodsi A et al. Characteristics, risk factors, and outcomes associated with readmission in COVID-19 patients: A systematic review and meta-analysis. Am J Emerg Med. 2022;52:166-173.

Zuil M, Benítez ID, Cabo-Gambín R, Manzano Senra C, Moncusí-Moix A, Gort-Paniello C et al. Clinical management and outcome differences between first and second waves among COVID-19 hospitalized patients: A regional prospective observational cohort. PLoS One. 2021;16:e0258918.

Hennekens CH, Rane M, Solano J, Alter S, Johnson H, Krishnaswamy S et al. Updates on Hydroxychloroquine in Prevention and Treatment of COVID-19. Am J Med. 2022;135:7-9.

Arabi YM, Gordon AC, Derde LPG, Nichol AD, Murthy S, Beidh F et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 2021;47:867-886.

Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L et al. Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine. 2021;384:693-704.

Rodríguez-Baño J, Pachón J, Carratalà J, Ryan P, Jarrín I, Yllescas M et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). Clinical Microbiology and Infection. 2021;27:244-252.

WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta- analyses. Lancet. 2022;399:1941-1953.

Weerakkody S, Arina P, Glenister J, Cottrell S, Boscaini-Gilroy G, Singer M et al. Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research. Lancet Respir Med. 2022;10:199-213.

Ramzi ZS. Hospital readmissions and post-discharge all-cause mortality in COVID-19 recovered patients; A systematic review and meta-analysis. Am J Emerg Med. 2022;51:267- 279.

Instituto de Salud Carlos III, Centro Nacional de Epidemiología, Red Nacional de Vilgilancia Epidemiológica. Informe nº 149. Situación de COVID-19 en España. Informe COVID-19. 4 de octubre de 2022. 2022.

Berenguer J, Borobia AM, Ryan P, Rodríguez-Baño J, Bellón JM, Jarrín I et al. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. Thorax. 2021;76:920-929.

Parra LM, Cantero M, Morrás I, Vallejo-Plaza A, Diego I, Jiménez-Tejero E et al. Hospital Readmissions of Discharged Patients with COVID-19. Int J Gen Med. 2020;Volume 13:1359- 1366.

Verna EC, Landis C, Brown RS, Mospan AR, Crawford JM, Hildebrand JS et al. Factors Associated With Readmission in the United States Following Hospitalization With Coronavirus Disease 2019. Clinical Infectious Diseases. 2022;74:1713-1721.

Finn A, Jindal A, Andrea SB, Selvaraj V, Dapaah-Afriyie K. Association of Treatment with Remdesivir and 30-day Hospital Readmissions in Patients Hospitalized with COVID-19. Am J Med Sci. 2022;363:403-410.

Xu H, Granger BB, Drake CD, Peterson ED, Dupre ME. Effectiveness of Telemedicine Visits in Reducing 30-Day Readmissions Among Patients With Heart Failure During the COVID-19 Pandemic. J Am Heart Assoc. 2022;11.

Nicolás D, Camós-Carreras A, Spencer F, Arenas A, Butori E, Maymó P et al. A Prospective Cohort of SARS-CoV-2-Infected Health Care Workers: Clinical Characteristics, Outcomes, and Follow-up Strategy. Open Forum Infect Dis. 2021;8.

Huang C-W, Desai PP, Wei KK, Liu I-LA, Lee JS, Nguyen HQ. Characteristics of patients discharged and readmitted after COVID-19 hospitalisation within a large integrated health system in the United States. Infect Dis. 2021;53:800-804.

Published

2024-03-19

How to Cite

1.
Roig-Sánchez N, Talaya Peñalver A, Poveda Ruiz N, del Pozo A, Hernández Campillo AM, Pérez Bernabéu A, et al. COVID-19 readmissions during the first three epidemic periods in Orihuela, Spain: incidence, risk factors and letality: e202403023. Rev Esp Salud Pública [Internet]. 2024 Mar. 19 [cited 2025 May 17];98:28 páginas. Available from: https://ojs.sanidad.gob.es/index.php/resp/article/view/403